HIV pre‐exposure prophylaxis (PrEP) is the use of antiretrovirals by HIV negative individuals to reduce the risk of HIV infection. In this article the authors give an overview of the evidence for PrEP among key populations and practical considerations regarding HIV and PrEP risk assessment, delivery and monitoring.